Result of AGM

26 April 2019 17:45 BST

Results of Annual General Meeting held on 26 April 2019

AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 1 – 8 were passed as ordinary resolutions and resolutions 9 – 12 were passed as special resolutions.

RESOLUTION VOTES FOR % OF VOTES CAST VOTES AGAINST % OF VOTES CAST VOTES CAST IN TOTAL TOTAL VOTES CAST AS A % OF   ISSUED SHARE CAPITAL VOTES WITHHELD
1 To receive the Company’s Accounts, the Reports of the Directors and   Auditor and the Strategic Report for the year ended 31 December 2018 1,002,386,773  99.96 381,361 0.04 1,002,768,134 76.44% 2,130,013
2 To confirm dividends 1,000,878,921 99.65 3,545,943 0.35 1,004,424,864 76.57% 474,696
3 To reappoint PricewaterhouseCoopers LLP as Auditor 1,003,208,151 99.90 1,002,311 0.10 1,004,210,462 76.55% 688,850
4 To authorise the Directors to agree the remuneration of the Auditor 1,002,479,345 99.82 1,794,309 0.18 1,004,273,654 76.56% 625,255
5a To re-elect Leif Johansson as a Director 998,953,618 99.51 4,884,897 0.49 1,003,838,515 76.53% 1,060,758
5b To re-elect Pascal Soriot as a Director 1,001,460,120 99.73 2,740,412 0.27 1,004,200,532 76.55% 699,226
5c To re-elect Marc Dunoyer as a Director 997,205,236 99.31 6,915,112 0.69 1,004,120,348 76.55% 775,679
5d To re-elect Geneviève Berger as a Director 993,018,194 99.77 2,314,964 0.23 995,333,158 75.88% 9,563,029
5e To re-elect Philip Broadley as a Director 995,659,475 99.16 8,475,542 0.84 1,004,135,017 76.55% 761,114
5f To re-elect Graham Chipchase as a Director 958,824,389 97.22 27,400,052 2.78 986,224,441 75.18% 18,671,390
5g To re-elect Deborah DiSanzo as a Director 1,001,808,208 99.77 2,336,040 0.23 1,004,144,248 76.55% 751,639
5h To re-elect Sheri McCoy as a Director 1,000,164,666 99.60 3,984,489 0.40 1,004,149,155 76.55% 746,732
5i To elect Tony Mok as a Director 1,003,431,827 99.93 699,122 0.07 1,004,130,949 76.55% 764,625
5j To re-elect Nazneen Rahman as a Director 1,001,687,441 99.76 2,413,171 0.24 1,004,100,612 76.55% 795,505
5k To re-elect Marcus Wallenberg as a Director 908,178,624 90.44 96,025,641 9.56 1,004,204,265 76.55% 691,663
6 To approve the Annual Report on Remuneration for the year ended 31   December 2018 947,606,599 95.86 40,895,170 4.14 988,501,769 75.36% 16,392,056
7 To authorise limited political donations 977,701,447 97.87 21,290,398 2.13 998,991,845 76.16% 5,895,452
8 To authorise the Directors to allot shares 877,861,679 87.43 126,178,566 12.57 1,004,040,245 76.54% 853,485
9 To authorise the Directors to disapply pre-emption rights 990,106,053 98.92 10,841,253 1.08 1,000,947,306 76.31% 3,944,848
10 To authorise the Directors to further disapply pre-emption rights for   acquisitions and specified capital investments 979,272,055 97.83 21,681,201 2.17 1,000,953,256 76.31% 3,939,912
11 To authorise the Company to purchase its own shares 994,069,976 99.04 9,657,377 0.96 1,003,727,353 76.52% 1,164,722
12 To reduce the notice period for general meetings 905,789,402 90.67 93,205,859 9.33 998,995,261 76.16% 5,902,125

Issued capital

As at 24 April 2019, the number of issued shares of the Company was 1,311,759,192 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all of the resolutions at the AGM. In accordance with the Company’s Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.

About AstraZeneca  

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in its main therapy areas - Oncology, CVRM and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @AstraZeneca.

Media Relations 
Gonzalo   Viña UK/Global +44 203 749 5916
Rob Skelding UK/Global +44 203 749 5821
Matt Kent UK/Global +44 203 749 5906 
Jennifer   Hursit UK/Global +44 203 749 5762
Christina   M Hägerstrand Sweden  +46   8 552 53 106 
Michele Meixell  US  +1 302 885 2677 
Investor Relations 
Thomas Kudsk   Larsen +44 203 749 5712
Henry Wheeler Oncology +44 203 749 5797
Christer Gruvris BioPharma -   Cardiovascular; Metabolism +44 203 749 5711
Nick Stone BioPharma -   Respiratory; Renal +44 203 749 5716
Josie Afolabi Other +44 203 749 5631
Craig Marks Finance; Fixed Income +44 7881 615 764
Jennifer Kretzmann Retail Investors; Corporate Access +44 203 749 5824
US toll-free +1 866 381 72 77

Adrian Kemp

Company Secretary

AstraZeneca PLC

About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit: www.astrazeneca.com

Subscribe

Documents & Links